Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

SciSparc Ltd. SPRC

10 fiscal years on record · USD · FY2024 reported · SEC filings only
$1.3M
▼ 54.6% YoY
$-6.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

We, through our subsidiary NeuroThera, engage in clinical-stage pharmaceutical developments. Our focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. We also have a majority-owned subsidiary, held by NeuroThera, whose business focuses on the sale of hemp seed oil-based products and others on Amazon Marketplace. SCI-110 is a proprietary drug candidate based on two components: (1) THC, which is the major cannabinoid molecule in the cannabis plant, and (2) CannAmide™, a proprietary PEA, formulation.

Written from the business description in SciSparc Ltd.'s annual report to the U.S. Securities and Exchange Commission, filed 29 April 2026. Every sentence was checked against that document before publication.

Growth

USD 1.3M
Revenue, FY2024 · full 10-year series below
Revenue $M Net income $M
FY2024 · Revenue 1.3 · Net income -6.3
1.5M3.0M-2.5M-5.0M
2015201820212024
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−572 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -560.2% · Net -572.1%
-200%-400%-600%
201520192024
ROE
FY2024 · ROE -79.7%
2000%4000%
201520192024
Three returns, three denominators.

Each USD of equity lost 80 cents this year.

Cash & shareholders

·
returned in FY2024 · dividends + net buybacks
Free cash flow $M
FY2022 · FCF -12.8
-5M-10M
201520192024

Total assetsUSD 10.3M
EquityUSD 8.2M
CashUSD 1.5M
Current ratio5.36×

Equity funds 79% of total assets.

The 10-year record

10 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SPRC, 10-year financial record
Metric 2024202320222021202020192018201720162015
Revenue $B0.00.00.0◌◌◌◌◌◌◌
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.00.0
EBITDA $B◌◌◌◌◌◌◌◌◌◌
Income tax $B−0.00.00.0◌◌◌−0.0◌◌◌
Net income $B−0.0−0.0−0.0−0.00.00.00.00.00.00.0
Free cash flow $B◌◌−0.0−0.0◌−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.2814.43−14.82−73.580.110.601.20◌◌◌
Dividend / sh $◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend——————————
ROE %−79.7−72.8−35.5−121.0489.64709.5198.8139.3230.7220.0
Shares out B0.010.000.010.000.000.230.140.140.04◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 2 failures in 35 reconciliationsAUDITED

Reconciled in 8 of the 10 fiscal years we could check. 18 checks were skipped: the balance sheet is not tagged before 2016. 15 checks were skipped: revenue is not tagged before 2022. 11 checks were skipped: EPS is not tagged before 2018.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency2 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code L3
Fiscal year endsDecember 31
Data on record since2015

Share this section

Download image